AM Investment Strategies LLC Raises Stock Holdings in Eli Lilly and Company $LLY

AM Investment Strategies LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 59.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,457 shares of the company’s stock after purchasing an additional 916 shares during the period. AM Investment Strategies LLC’s holdings in Eli Lilly and Company were worth $1,875,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. lifted its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth $31,000. Finally, Bare Financial Services Inc lifted its holdings in Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday, November 10th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Finally, UBS Group began coverage on Eli Lilly and Company in a research note on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 price objective on the stock. Five research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Stock Up 0.2%

Shares of Eli Lilly and Company stock opened at $1,040.95 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market cap of $984.09 billion, a P/E ratio of 50.93, a PEG ratio of 0.78 and a beta of 0.35. The firm’s 50 day moving average price is $1,053.86 and its 200-day moving average price is $875.14. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s sofetabart mipitecan for certain platinum‑resistant ovarian cancers — a meaningful validation for Lilly’s oncology pipeline that diversifies revenue beyond GLP‑1 drugs and could accelerate development/partnering value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: Phase results: Lilly’s Taltz combined with Zepbound showed superior results in a landmark psoriatic‑arthritis trial — suggests label expansion and additional commercial upside for existing franchises. Eli Lilly’s Taltz and Zepbound combo delivers superior results
• Positive Sentiment: Analyst/media bullishness: Several outlets (MarketBeat, The Motley Fool) highlight Lilly as a top play in 2026 because Zepbound and Mounjaro drive rapid growth and the company has late‑stage assets (Alzheimer’s, oncology, CV) that could sustain upside. That framing supports multiple expansion narratives. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
• Positive Sentiment: Longer‑term growth thesis reinforced: The Motley Fool argues 2026 could be “the year of Eli Lilly,” pointing to the company’s weight‑loss portfolio (recent quarter ~ $10B) and upcoming catalysts — a narrative that attracts growth investors. Prediction: 2026 Will Be the Year of Eli Lilly
• Neutral Sentiment: Analyst note: Guggenheim trimmed its price target slightly (from $1,163 to $1,161) but kept a “buy” rating — a minor technical change that maintains analyst bullishness and implies continued upside from current levels. LLY price target lowered by Guggenheim
• Neutral Sentiment: Takeover speculation calmed: Reports that Lilly might bid for Abivax circulated, but Abivax’s CEO dismissed the rumors as “noise,” removing an M&A upside narrative (so neutral-to-cooling for any takeover-driven pop). Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
• Neutral Sentiment: Industry comparison pieces (Zacks, Blockonomi) reiterate Lilly’s strength from Mounjaro/Zepbound and note an oral GLP‑1 near approval — these are context pieces that support the growth story but also flag competitive dynamics to watch. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Negative Sentiment: Competitive risk: Novo Nordisk’s new oral Wegovy pill showed very fast initial prescriptions after launch, and analysts note rising competition as oral formulations and other entrants scale — a development that could pressure Lilly’s market share and future growth if its oral GLP‑1 underperforms or is delayed. Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.